A recent article published on the bioRxiv* preprint server reports that the coronavirus disease 2019 (COVID-19) NVX-CoV2373 vaccine triggers robust neutralization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants.
The SARS-CoV-2 Omicron variant of concern (VOC) and its subvariants BA.4, BA.5, BA.2, and BA.2.12.1 possess numerous spike (S) mutations that are responsible for the high level of resistance observed against COVID-19 vaccine-induced neutralization, irrespective of the vaccine platform. Likewise, individuals with a history of prior COVID-19 also exhibit reduced neutralizing titers against several Omicron subvariants. Novavax vaccine the Nevertheless, booster vaccination has been shown to improve Omicron neutralizing capacity, particularly with messenger ribonucleic acid (mRNA) vaccines.
Novavax vaccine NVX-CoV2373 is a COVID-19 protein nanoparticle vaccine that has been particularly useful in nations with limited cold-chain requirements. The NVX-CoV2373 vaccine is listed in the World Health Organization (WHO) emergency use category for COVID-19 vaccines and has been granted usage authorization by the European Medicines Agency In the current study, researchers report SARS-CoV-2 neutralizing titers, including those against several Omicron sublineages, after double and triple vaccination with the NVX-CoV2373 vaccine. To this end, they evaluated how a third dose affected the ability of the NVX-CoV2373 vaccine recipients’ sera to neutralize SARS-CoV-2 and these variants. The neutralization of the SARS-CoV-2 ancestral D614G, Omicron BA.4, BA.1, BA.5, and Beta strains by the sera of 29 and 48 NVX-CoV2373 vaccine recipients was assessed after completion of a two- and three-dose vaccine regimens, respectively. Omicron BA.4, BA.5, and BA.1 neutralization were also assessed after multiple doses of mRNA, adenoviral, and protein-based COVID-19 vaccines.
Source: This news is originally published by news-medical.net